流式细胞术外周血CD22参考区间的建立

余晾; 赵皓; 袁晓英; 宋英; 李佳佳

doi:10.16766/j.cnki.issn.1674-4152.003326

流式细胞术外周血CD22参考区间的建立

doi: 10.16766/j.cnki.issn.1674-4152.003326

余晾^1, ,,
赵皓¹,
袁晓英²,
宋英³,
李佳佳⁴

1.
蚌埠医科大学第一附属医院中心实验室，安徽蚌埠 233004
2.
北京大学人民医院血液科实验室，北京 100044
3.
北京大学人民医院检验科
4.
蚌埠医科大学院第一附属医院血液科

基金项目:

安徽高校自然科学研究项目 KJ2019A0358

详细信息

通讯作者:
余晾，E-mail：37599938@qq.com

中图分类号: R446.11
计量
- 文章访问数: 83
- HTML全文浏览量: 20
- PDF下载量: 17
- 被引次数: 0
出版历程
- 收稿日期: 2023-05-30
- 网络出版日期: 2024-03-09

Establishment of CD22 reference intervals in peripheral blood by flow cytometry

1.
Central Laboratory, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

摘要

摘要: 目的通过流式细胞术检测健康成人外周血中CD22占淋巴细胞的百分比，采用国际临床实验室标准化委员会EP28-A3c的要求分析并建立适合健康成人的参考值范围。方法收集2022年7—11月在北京大学人民医院及蚌埠医科大学第一附属医院健康体检者外周血，采用流式细胞术测定130例健康成年人外周血CD22水平，同时依据EP28-A3c文件中分组要求按地区、性别、年龄进行分组并对各组数据进行分析，从而建立对应的生物参考区间。结果健康成人外周血CD22水平呈正态性分布，北京地区与安徽地区健康成人外周血CD22阳性率分别为(10.87±4.37)%和(12.62±4.03)%，差异无统计学意义(t=1.336，P=0.205)；男性、女性组外周血CD22阳性率分别为(11.76±4.86)%和(11.85±3.69)%，差异无统计学意义(t=0.111，P=0.911)；按年龄分为≤35周岁组、36~60周岁组及＞60周岁组，3组外周血CD22阳性率分别为(11.53±3.20)%、(11.61±3.80)%和(12.73±6.36)%，差异无统计学意义(F=0.761, P=0.469)。参照国际临床实验室标准化委员会推荐的90%可信区间确定CD22占淋巴细胞比例(流式细胞术)的参考值范围为4.82%~18.80%。结论 CD22占淋巴细胞比例(流式细胞术)的参考范围在不同地区、性别、年龄的结果较为一致，可以合并建立健康成人外周血中CD22阳性率的参考区间。
- CD22 /
- 流式细胞术 /
- 参考区间
Abstract: Objective To detect the percentage of CD22 in peripheral blood lymphocytes of healthy adults by flow cytometry. The reference range for healthy adults was established according to the requirements of Clinical and Laboratory Standards Institute EP28-A3c. Methods Peripheral blood was collected from healthy people who underwent physical examination in Peking University People' s Hospital and the First Affiliated Hospital of Bengbu Medical University from July to November 2022. The peripheral blood CD22 levels of 130 healthy adults were measured by flow cytometry, and the data of each group were grouped according to region, sex and age according to the grouping requirements in the EP28-A3c file, so as to establish the corresponding biological reference interval. Results The level of CD22 in peripheral blood of healthy adults was normally distributed, and the positive rates of CD22 in peripheral blood of healthy adults in Beijing and Anhui were (10.87±4.37)% and (12.62±4.03)%, respectively, with no statistical significance (t=1.336, P=0.205). The positive rates of CD22 in male and female peripheral blood were (11.76±4.86)% and (11.85±3.69)%, respectively, and the difference was not statistically significant (t=0.111, P=0.911). They were divided into ≤35 years old group, 36-60 years old group and > 60 years old group. The positive rate of CD22 in peripheral blood of the three groups were (11.53±3.20)%, (11.61±3.80)% and (12.73±6.36)%, respectively, and there was no statistical significance (F=0.761, P=0.469). According to the 90% confidence interval recommended by the International Committee for Clinical Laboratory Standards, the reference intervals of CD22 in lymphocytes (flow cytometry) was 4.82%-18.80%. Conclusion The reference intervals of CD22 positive rate in peripheral blood of healthy adults are consistent in different regions, gender and age. It can be combined to establish the reference intervals of CD22 positive rate in peripheral blood of healthy adults.
- CD22 /
- Flow cytometry /
- Reference intervals

HTML全文

表 1 不同地区健康成人CD22测定值比较(x±s, %)

Table 1. Comparison of CD22 ratios in healthy adultsacross different regions(x±s, %)

地区	例数	CD22
北京	60	11.35±4.21
蚌埠	70	12.21±3.78
t值		1.219
P值		0.225

下载: 导出CSV

表 2 不同年龄健康成人CD22测定值比较(x±s, %)

Table 2. Comparison of CD22 ratios in healthy adults with different ages(x±s, %)

年龄组	例数	CD22
≤35周岁	41	11.53±3.20
36~60周岁	63	11.61±3.80
＞60周岁	26	12.73±6.36
F值		0.761
P值		0.469

下载: 导出CSV

表 3 不同性别健康成人CD22测定值比较(x±s, %)

Table 3. Comparison of CD22 ratios in healthy adults with different genders (x±s, %)

性别	例数	CD22
男性	61	11.76±4.86
女性	69	11.85±3.69
t值		0.111
P值		0.911

下载: 导出CSV

参考文献(19)

[1]	武晓静, 邵宗鸿. CD22表达、功能及调控的研究进展[J]. 中国实验血液学杂志, 2015, 23(2): 573-577. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201502058.htm WU X J, SHAO Z H. Recent advances of researches on expression, function and regulation of CD22 review[J]. Journal of Experimental Hematology, 2015, 23(2): 573-577. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201502058.htm
[2]	Clinical and Laboratory Standards Institute. Defining, establishing, and verifying reference intervals in the clinical laboratory; Approved guideline-third edition. NCCLS Document EP28-A3c[M]. Wayne, PA: Clinical and Laboratory Standards Institute, 2010.
[3]	AKATSU C, SHEIKH A A, MATSUBARA N, et al. The inhibitory coreceptor CD22 restores B cell signaling by developmentally regulating Cd45^-/- immunodeficient B cells[J]. Sci Signal, 2022, 15(723): eabf9570. DOI: 10.1126/scisignal.abf9570.
[4]	李薇, 曾伟杰, 彭浩, 等. CD19和CD22双靶点CAR-T细胞对肿瘤细胞的杀伤作用[J]. 中国肿瘤生物治疗杂志, 2022, 29(7): 623-630. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW202207003.htm LI W, ZENG W J, PENG H, et al. The killing effect of CD19 and CD22 dual target CAR T cells on tumor cells[J]. Chinese Journal of Tumor Biotherapy, 2022, 29(7): 623-630. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLSW202207003.htm
[5]	徐童, 刘辉. 嵌合抗原受体T细胞治疗血液肿瘤的研究进展[J]. 中华微生物学和免疫学杂志, 2021, 41(7): 560-564. doi: 10.3760/cma.j.cn112309-20210520-00167 XU T, LIU H. Research progress of chimeric antigen receptor T cells therapy in hematological malignancies[J]. Chinese Journal of Microbiology and Immunology, 2021, 41(7): 560-564. doi: 10.3760/cma.j.cn112309-20210520-00167
[6]	BODET-MILIN C, FERRER L, PALLARDY A, et al. Preclinical basis for lymphoma treatment with the CD22-targeting antibody-drug conjugate pinatuzumab vedotin[J]. BJH, 2020, 188(3): 460-477. doi: 10.1111/bjh.16179
[7]	FRY T J, SHAH N N, ORENTAS R J, et al. CD22-targeted CAR-T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy[J]. Nat Med, 2018, 24(1): 20-28. doi: 10.1038/nm.4441
[8]	穆娟, 吕海容, 李静怡, 等. CD22 CAR-T挽救治疗CD19 CAR-T治疗后短期复发的TP53突变阳性难治急性B淋巴细胞白血病一例[J]. 天津医药, 2020, 48(4): 308-312. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ202004016.htm MU J, LYU H R, LI J Y, et al. CD22 CAR-T salvage therapy for a refractory acute B lymphocytic leukemia patient with TP53 positive mutation and short-term recurrence after remission from CD19 CAR-T therapy[J]. Tianjin Medical Journal, 2020, 48(4): 308-312. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ202004016.htm
[9]	丁雅雯, 王芃堉, 焦文静, 等. 弥漫大B细胞淋巴瘤骨髓侵犯形态学及免疫表型特点分析[J]. 天津医药, 2020, 48(3): 204-208. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ202003011.htm DING Y W, WANG P Y, JIAO W J, et al. Analysis of morphological and immunophenotypic features of bone marrow invasion in diffuse large B-cell lymphoma[J]. Tianjin Medical Journal, 2020, 48(3): 204-208. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ202003011.htm
[10]	王雯娟, 赵娟, 贺鹏程, 等. 淋巴瘤细胞白血病骨髓细胞形态学和免疫分型的特点及其在诊断中的价值[J]. 中国实验血液学杂志, 2018, 26(2): 459-463. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201802030.htm WANG W J, ZHAO J, HE P C, et al. Characteristics and Diagnostic Values of Bone Marrow Cell Mor-phology and Immunophenotyping in Lymphoma Cell Leukemia[J]. Journal of Experimental Hematology, 2018, 26(2): 459-463. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201802030.htm
[11]	周月平. 骨髓形态联合免疫分型检测在慢性淋巴细胞白血病中的应用[J]. 中国当代医药, 2020, 27(24): 158-160. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD202024043.htm ZHOU Y P. Application of marrow morphology combined immunotyping in chronic lymphoblastic leukemia[J]. China Modern Medicine, 2020, 27(24): 158-160. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD202024043.htm
[12]	赵雪飞, 王洪岩, 赵旭, 等. 急性淋巴细胞白血病的免疫分型和基因的研究[J]. 中国实验血液学杂志, 2018, 26(4): 947-952. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201804004.htm ZHAO X F, WANG H Y, ZHAO X, et al. Study on Immunophenotypes and Gene of Acute Lymphoblastic Leukemia[J]. Journal of Experimental Hematology, 2018, 26(4): 947-952. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201804004.htm
[13]	裴东旭, 张鹏, 段晓克, 等. CLLflow和Moreau评分系统对慢性淋巴细胞白血病诊断效能比较[J]. 中华检验医学杂志, 2023, 46(1): 81-86. PEI D X, ZHANG P, DUAN X K, et al. Diagnostic efficacy comparison between CLLflow score and Moreau score for chronic lymphocytic leukemia[J]. Chinese Journal of Laboratory Medicine, 2023, 46(1): 81-86.
[14]	KANTARJIAN H M, DAANGELO D J, STELLJES M, et al. Inotuzumabozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study[J]. Cancer, 2019, 125(14): 2474-2487. doi: 10.1002/cncr.32116
[15]	徐力, 聂柳燕, 汪胡燕, 等. 自身免疫性疾病中程序性细胞死亡因子1及其配体的研究进展[J]. 中华全科医学, 2022, 20(5): 832-835, 843. doi: 10.16766/j.cnki.issn.1674-4152.002466 XU L, NIE L Y, WANG H Y, et al. Research progress of programmed cell death-1 and its ligand in autoimmune diseases[J]. Chinese Journal of General Practice, 2022, 20(5): 832-835, 843. doi: 10.16766/j.cnki.issn.1674-4152.002466
[16]	王欣, 张庆, 罗帅寒天, 等. 系统性红斑狼疮治疗靶点相关研究进展[J]. 中南大学学报(医学版), 2021, 46(11): 1267-1275. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYD202111013.htm WANG X, ZHANG Q, LUO S H T, et al. Advances in therapeutic targets-related study on systemic lupus erythematosus[J]. Journal of Central South University, 2021, 46(11): 1267-1275. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYD202111013.htm
[17]	王晓霞, 王洪, 何佳莉, 等. 我国风湿性疾病药物临床试验现状分析[J]. 中华风湿病学杂志, 2020, 24(4): 240-246. WANG X X, WANG H, HE J L, et al. Analysis of drug clinical trials for rheumatic diseases in China[J]. Chinese Journal of Rheumatology, 2020, 24(4): 240-246.
[18]	BRANDL C, ANGERMULLER S, NITSCHKE L, et al. Humanized CD22 transgenic mouse model for in vivo analysis of anti-CD22-based immunotherapy[J]. Eur J Immunol, 2020, 50(11): 1834-1837.
[19]	BEDNAR K J, NYCHOLAT C M, RAO T S, et al. Exploiting CD22 to selectively tolerize autoantibody producing B-cells in rheumatoid arthritis[J]. ACS Chem Biol, 2019, 14(4): 644-654.